Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Scroll down and select country
MEBO TMAU TESTING CURRENTLY SUSPENDED INDEFINITELY

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

London TMAU meeting with Prof Liz Shephard
19th Oct 11am - 1pm
St Mary's Hospital
Praed St, Paddington
London W2 1NY
click to read more
more details : karen.james@meboresearch.org

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Friday, April 15, 2011

TMAU Test and Liquid Chromatography/Mass Spectrometry

As mentioned in my latest Update post dated April 1 in this Blog, Eliapharma has been working on analyzing TMA levels, TMAO levels, and creatinine of the first 38 specimens received. However, Samir was not satisfied with the sensitivity level of the test, as he explains below,


We have performed a method of analysis developed in the past, but this method was not as sensitive as we would have liked, because in order to bring more sensitivity to the test, we have had to compromise the selectivity of the method. Consequently, Eliapharma is obtaining two analytical columns that we have purchased from Japan, which combines polar and non polar groups. Once we obtain and install these columns, I am confident that we will be successful in obtaining excellent chromatography, sensitivity, and selectivity.

Samir Nassr, M.Sc., CEO
Eliapharma Services Inc.
230 Bernard Belleau suite 166
Laval, QC, Canada, H7V 4A9


Once we obtain and install these columns, I am confident that we will be successful in obtaining excellent chromatography, sensitivity, and selectivity.
Samir Nassr, M.Sc., CEO
ABOUT THE ACCURACY OF THE TEST: Many labs have been using a gas chromatography equipment for TMAU testing; and a newer system has come out in the market, the Liquid Chromatography/Mass Spectrometry. If I am not mistaken, I believe that there is a lab in New Zealand and another in Korea that have the new liquid LC/MS. Scientists in the Korea Institute of Science and Technology have written a paper in the Korean Chemical Society Jounal (KCS), Determination of Urinary Trimethylamine and Trimethylamine N-oxide by Liquid Chromatography-Tandem Mass Spectrometry Using Mixed-Mode Stationary Phases(1).

Since TMA is a small molecule and thus is more difficult to detect and measure, Eliapharma's CEO was not satisfied with the results he got in his first 2 and 3 rounds of tests, and he made some adjustments on the equipment until he was better satisfied with it, but still not 100% satisfied. After an indepth analysis, Samir has determined that he needs to purchase two columns (attachments), Capcell Pak CR part no. 93026 to attach to his LC-MS/MS Bioanalysis equipment for this test in order to achieve greater sensitivity and selectivity in the results. So he has ordered it (price $1,500). Samir will not give us to distribute the 3 results of all the tests he's done, until he gets this part and runs the test of all the samples again. Once these columns are attached to the LC/MS, it would guarantee excellent chromatography, sensitivity, and selectivity when working with this small molecules such as TMA.

Meanwhile, Samir informs us that he will run the test again with any and all samples he may have at the time at his lab, before the columns arrive. He will then give these results to MEBO, and if anyone who has tested wishes to discuss these results with me in advance to have a rough idea of how their choline load has affected them, they may email me to set up a private phone call. However, it will be necessary to wait until the columns have been received and the test re-done for accurate results for the sufferer to give to their doctor.

With the shipment of new kits that will go out from the lab on Monday, there will have been 61 samples tested if all are returned before the columns are received.

Everyone's patience is greatly appreciated.

María

María de la Torre
President and Executive Director
A Public Charity
www.meboresearch.org
maria.delatorre@meboresearch.org
MEBO's Blog (English)
El Blog de MEBO (español)

(1)Sang Kyu Lee, Dong-Hyun Kim, Changbae Jin, and Hye Hyun Yoo; Bull. Korean Chem. Soc. 2010, Vol.31, No.2, DOI 10.5012/bkcs.2010.31.02.483

0 comments:

Post a Comment